Cytosorbents (NASDAQ:CTSO) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Cytosorbents (NASDAQ:CTSO) in a report issued on Tuesday morning. The brokerage issued a hold rating on the medical research company’s stock.

A number of other equities analysts also recently issued reports on the company. HC Wainwright reiterated a neutral rating and set a $1.00 price target on shares of Cytosorbents in a research note on Tuesday, May 7th. EF Hutton Acquisition Co. I upgraded Cytosorbents to a strong-buy rating in a report on Monday, July 29th. Finally, B. Riley restated a buy rating and set a $3.00 price objective on shares of Cytosorbents in a research note on Wednesday, May 15th.

Cytosorbents Trading Up 1.0 %

Shares of Cytosorbents stock traded up $0.01 on Tuesday, hitting $1.05. 18,133 shares of the company’s stock traded hands, compared to its average volume of 131,662. The company has a market capitalization of $57.02 million, a price-to-earnings ratio of -1.78 and a beta of 0.57. Cytosorbents has a one year low of $0.70 and a one year high of $3.09. The company has a debt-to-equity ratio of 0.10, a current ratio of 1.49 and a quick ratio of 1.21. The company has a fifty day moving average of $0.95 and a two-hundred day moving average of $0.94.

Cytosorbents (NASDAQ:CTSO) last issued its earnings results on Thursday, May 9th. The medical research company reported ($0.12) EPS for the quarter, meeting the consensus estimate of ($0.12). The company had revenue of $9.79 million during the quarter, compared to the consensus estimate of $9.78 million. Cytosorbents had a negative return on equity of 129.89% and a negative net margin of 75.07%. During the same period last year, the business posted ($0.17) EPS. As a group, sell-side analysts expect that Cytosorbents will post -0.36 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Sargent Investment Group LLC boosted its stake in Cytosorbents by 4.9% in the second quarter. Sargent Investment Group LLC now owns 1,433,500 shares of the medical research company’s stock valued at $1,008,000 after acquiring an additional 67,181 shares during the last quarter. CM Management LLC increased its position in Cytosorbents by 3.0% in the second quarter. CM Management LLC now owns 850,000 shares of the medical research company’s stock worth $598,000 after buying an additional 25,000 shares during the last quarter. Avenir Corp lifted its position in shares of Cytosorbents by 4.0% during the 1st quarter. Avenir Corp now owns 3,172,696 shares of the medical research company’s stock valued at $3,014,000 after buying an additional 121,294 shares during the last quarter. Key Client Fiduciary Advisors LLC increased its holdings in Cytosorbents by 188.0% in the 1st quarter. Key Client Fiduciary Advisors LLC now owns 34,557 shares of the medical research company’s stock worth $33,000 after acquiring an additional 22,557 shares during the last quarter. Finally, Neuberger Berman Group LLC grew its stake in Cytosorbents by 19.9% in the 4th quarter. Neuberger Berman Group LLC now owns 1,801,799 shares of the medical research company’s stock worth $1,997,000 after buying an additional 299,103 shares in the last quarter. Institutional investors own 32.87% of the company’s stock.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.